Expand AYTU Menu
AYTU MENU

AYTU Latest Press Releases

-- February 3, 2026 --

Aytu BioPharma Reports Fiscal 2026 Second Quarter Operational and Financial Results ACCESS Newswire 4:05 PM

-- January 27, 2026 --

Aytu BioPharma to Report Fiscal 2026 Second Quarter Operational and Financial Results on February 3, 2026 ACCESS Newswire 4:05 PM

-- January 20, 2026 --

Aytu BioPharma Recaps Investor Day Held on January 20, 2026 ACCESS Newswire 4:05 PM
Aytu BioPharma Highlights Opportunity for EXXUATM (gepirone) as New Way to Treat Major Depressive Disorder That Avoids Common Side Effects of Sexual Dysfunction and Significant Weight Gain following launch of EXXUA ACCESS Newswire 9:00 AM

-- December 18, 2025 --

Aytu BioPharma to Host Investor Day on January 20, 2026 in New York City ACCESS Newswire 9:00 AM

-- December 15, 2025 --

Aytu BioPharma Announces Commercial Availability of EXXUA(TM) (gepirone) Extended-Release Tablets, the First and Only 5HT1a Agonist Indicated for the Treatment of Major Depressive Disorder in Adults ACCESS Newswire 9:00 AM

-- November 24, 2025 --

Aytu BioPharma to Participate in Noble Capital Markets 21st Annual Emerging Growth Equity Conference ACCESS Newswire 4:05 PM

-- November 13, 2025 --

Aytu BioPharma Reports Fiscal 2026 First Quarter Operational and Financial Results ACCESS Newswire 4:05 PM

-- November 5, 2025 --

Aytu BioPharma to Report Fiscal 2026 First Quarter Operational and Financial Results on November 13, 2025 ACCESS Newswire 4:05 PM

-- October 28, 2025 --

Aytu BioPharma Announces Patent Term Extension for EXXUA(TM) ACCESS Newswire 9:00 AM

-- October 10, 2025 --

Aytu BioPharma to Present at Upcoming October 2025 Conferences ACCESS Newswire 9:00 AM
Market Data Delayed 15 Minutes